ArticleInternational journal of endocrinology2012
Medical therapy of acromegaly.
Article in International journal of endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- [The role of glucose and insulin in the metabolic regulation of growth hormone secretion].Problemy endokrinologii · 2021Review
- Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly.Patient preference and adherence · 2016Review
- Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Journal of endocrinological investigation · 2015Article
- Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.Pituitary · 2015Review
- Article
- Whole-body insulin sensitivity rather than body-mass-index determines fasting and post-glucose-load growth hormone concentrations.PloS one · 2014Article
- Article
- Pharmacoeconomic aspects of the treatment of pituitary gland tumours.Contemporary oncology (Poznan, Poland) · 2013Article
- Acromegaly: role of surgery in the therapeutic armamentarium.International journal of endocrinology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated. Therapeutic efficacy of the different available drugs-somatostatin receptor ligands (SRLs), dopamine agonists, and the GH antagonist Pegvisomant-is discussed, as are the indications for and efficacy of their respective combinations. Information on their mechanism of action, and some pharmakokinetic data are included. Special emphasis is given to the difficulties to define remission criteria of acromegaly due to technical assay problems. An algorithm for medical therapy in acromegaly is provided.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.